Lilly Undeterred By UK NICE Funding Blow For Second-Line Use Of Verzenios
UK HTA Body Has Issued A Preliminary Rejection Of Breast Cancer Drug For Routine Use
Verzenios is one of three CDK4/6 inhibitors that are available via the Cancer Drugs Fund for use in previously treated patients with metastatic breast cancer, but it is the first for which health technology assessment body NICE has published a recommendation on routine commissioning.
You may also be interested in...
The decision by health technology assessment body NICE on Novartis’s advanced breast cancer drug, Kisqali, contrasts sharply with its recommendation for another CDK4/6 inhibitor – Lilly’s Verzenios.
Pfizer’s Ibrance has won conditional reimbursement in England while more data is gathered to reduce some uncertainty.
Health technology assessment body NICE says that Verzenios when used with fulvestrant can be used to treat advanced breast cancer via the Cancer Drugs Fund, giving Eli Lilly the edge in this space for now over rival CDK4/6 manufacturers, Pfizer and Novartis.